Mesoblast (NASDAQ:MESO) is a biotech company in Melbourne focusing on regenerative medicine. It's developing rexlemestrocel-L and remestemcel-L, with FDA approvals pending. With 3 hedge fund investors, MESO ranks 5th in ASX stocks.